What changed from existing technology?
This study used single-cell analysis to find different types of B cell lymphoma that can predict how well patients respond to treatment.
This is the first study to identify distinct malignant B cell archetypes within individual tumors that correlate with clinical outcomes in large B cell lymphomas.
Commercialization signals visible at publication
This is not a success probability or investment opinion. It prioritizes follow-up using evidence available when the paper was published.
Verified evidence · 2
ads to disparate treatment response, with up to 40% of patients developing refractory disease or relapsing within the first two years. To understand the cellu
Abstract ↗OpenAlex author affiliations: Bristol-Myers Squibb (United States), Bristol-Myers Squibb (Germany), Bristol-Myers Squibb (Sweden)
Abstract ↗- 시제품·장치 구현 근거 미확인
- 제조·규모 확장 근거 미확인
Later patent, company, clinical, and production events are added separately only after verification.
Patent check: Not checked yetCurrent technology stage: Near commercialization
See what changed before reading the full paper.
What still needs to be solved?
Repeated real-world validation, manufacturability, cost, and long-term stability still require follow-up evidence.
What could change if this succeeds?
The identified archetypes may help in predicting patient response to standard immunochemotherapy and guide personalized treatment strategies.
Keep following this technology
Revisit changes when new papers, patents, company participation, validation, or products appear.
Evidence and sources
View paper and author affiliations
Open original researchA single-cell atlas of large B cell lymphomas reveals distinct malignant archetypes predictive of clinical outcomesBlood · Published 2026-09-17 ↗Author institutions and listed legal entities are separated; only verified exchange and ticker data is linked.